FC:AI · OPEN SOURCE ME · CANCER PROFILE

Russ Read-Barrow

DOB 2 July 1982 · Bath, UK · Treated at The Bath Clinic, Claverton Down, Bath
No known drug allergies · WHO performance status 0

CORRECT AS AT
17 SEPTEMBER 2026
Check the QR code for the latest version

On treatmentCycle 3 of FOLFIRI + cetuximab rechallengeCycle 4 due 30 Sep 2026 · CT after Cycle 5

Stage

Metastatic

CEA

50.9

ug/L · 14 Sep 26 · ref 0–5.2

Cycle

of this block · 15th FOLFIRI+cetux overall

WHO PS

Fully active · 24 Aug 26

PD-L1

<1%

TPS · negative

Diagnosis

Moderately differentiated adenocarcinoma, rectosigmoid colon

ypT4a ypN1b (3/24 nodes) M1a V+ · Treatment began Dec 2021; primary resected Mar 2022

Where it is now: Lungs · mediastinal lymph nodes · liver segment VII (new, Jul 2026)

Smouldering myeloma (diagnosed end of 2021, under haematology surveillance)
Gilbert's syndrome (can raise bilirubin)

Molecular profile EXACTA report, 1 Sep 2025

KRAS/NRAS wild-typeBRAF wild-typepMMR / MSSHER2 IHC 0TMB-low · 3 Mut/MbPD-L1 <1% (22C3, 28-8)

APC p.S1415Rfs*4Pathogenic

Frameshift · tissue MAF 8.5% · cfDNA 0.62%

TP53 p.R342*Pathogenic

Nonsense · tissue MAF 9.21%

PTEN reported, not specifiedTo confirm

Named in my oncology letters. Exact variant, allele fraction and classification not in my records yet

VUS: RUNX1T1, FANCM, CIC, BCR, CYP2D6. Exploratory (Astron/ICC): MTOR and VEGFR1/2 protein positivity, HMGB1 overexpression

Current treatment 14 days cycles

FOLFIRI + cetuximab (rechallenge, 3rd block)

C119 Aug 26

C22 Sep 26

C316 Sep 26

C430 Sep 26

C5TBC

Cetuximab500 mg/m²1000 mg

Irinotecan180 mg/m²400 mg

5-FU bolus400 mg/m²900 mg

5-FU infusion (46h)2400 mg/m²5000 mg

Folinic acid350 mg

Full doses, dose-banded · BSA 2.08 m² (84.5 kg, 185 cm, 16 Sep 26)

Plan: 8–12 weeks, then consider maintenance 5-FU + cetuximab if response is good. CT after Cycle 5.

CEA tumour marker ug/L

FOLFIRI + cetuximab blocks · 19 readings, Apr 2025 – Sep 2026

Key bloods 14 Sep 2026

Haemoglobin133 g/L

White cells6.64 ×10⁹/L

Neutrophils3.99 ×10⁹/L

Platelets289 ×10⁹/L

ALT26 U/L

AST26 U/L

ALP179 U/L H

Bilirubin13 µmol/L

Albumin43 g/L

Globulin37 g/L H

Creatinine75 µmol/L

Magnesium0.89 mmol/L

Potassium4.2 mmol/L

GGT22 U/L

Latest imaging

23 Jul 2026 · CT chest, abdomen & pelvis

Progression above and below the diaphragm, and a new liver metastasis

CT report, 23 Jul 2026, compared with May 2026

Before that: 12 May 2026, CT chest, abdomen & pelvis: “Good response to treatment within the mediastinum and lungs.”

Treatment history

Dec 21–Feb 22Neoadjuvant XELOX ×4 · good partial response
Mar–Oct 22Primary resected · liver met resected (R0) · adjuvant CAPOX
Oct 22–Apr 23Lung mets appear, progress · SABR 55 Gy/5
Jun & Aug 24Lung ablations (1 left, then 1 left + 4 right)
Feb 25EBUS confirms mediastinal nodal disease
Apr–Jul 25FOLFIRI + cetuximab ×6 · good partial response
Feb–May 26Rechallenge ×6 · excellent partial response
Jul–Aug 26Progression during the break · FOLFIRI + cetuximab restarted 19 Aug

Medication & protocol Current meds · 17 Sep

Chemo dayStandard pre-meds (Akynzeo, dexamethasone, chlorphenamine, atropine) · pegfilgrastim 24h after

SupportiveDexamethasone ×3 days · domperidone · loperamide · doxycycline + Plazon (skin) · Laxido · antihistamine · zopiclone PRN

OtherCitalopram 30 mg (breakfast) · melatonin 60 mg (evening) · loratadine 10 mg

PausedMistletoe and most supplements / off-label drugs, during chemo on my oncologist's advice

What I'm looking into

BNT314 + pumitamig (BNT327) + chemo · MSS/pMMR mCRC
Botensilimab + balstilimab · pre-treated MSS CRC
WNT/β-catenin-targeted: ST316 (NCT05848739, phase 1–2) · tegavivint

Know this profile? Patients with similar disease, oncologists, scientists and geneticists — I want to hear from you. Not generic advice, please.